"Parse showed a leap-and-a-point significant progress in the past year, and the market demand for the company's Evercode single-cell sequencing solution has grown significantly." Dr. Alex Rosenberg, CEO and co-founder of Parse, said, "Partnerships with first-class suppliers in the Middle East will help consolidate our foundation in the area and then drive subsequent growth."

The agreement between Parse and Ornat will give Israeli researchers the opportunity to access the company's full portfolio of single-cell products, including Evercode™ Whole Transcriptome, Evercode TCR, Evercode Cel l Fixation, Evercode Nuclei Fixation, Gene Capture and Parse Biosciences data analysis solutions. The agreement will benefit Parse's plan to bring products into important international markets.

Parse is using Evercode technology to accelerate single-cell research. We are very happy to cooperate with them to introduce this advanced technology to the thriving Israeli biotechnology circle." Eyal Lev, CEO of Ornat, said.